Effects of different doses of remifentanil on the end-tidal concentration of sevoflurane required for tracheal intubation in children.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 19604188.
- Also identified by DOI 10.1111/j.1365-2044.2009.05942.x.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We investigated the effects of different doses of remifentanil on the end-tidal concentration of sevoflurane required for tracheal intubation in children without the use of neuromuscular blocking drugs. One hundred and thirty paediatric patients, aged 3-8 years, were randomly allocated to receive no remifentanil (group control) or remifentanil 0.1 microg kg(-1) min(-1) (group remi(0.1)), 0.2 microg kg(-1) min(-1) (group remi(0.2)), 0.3 microg kg(-1) min(-1) (group remi(0.3)). All patients were anaesthetised using 5% sevoflurane. After loss of eyelash reflex, remifentanil 1 microg kg(-1) was injected over 1 min followed by an appropriate group-dependent infusion and the end-tidal sevoflurane concentration was changed. Predetermined end-tidal sevoflurane concentrations for each group were determined using the Dixon up-and-down method. After the target concentration of sevoflurane was maintained for 5 min, the child's trachea was intubated. Successful intubation was defined as excellent or good intubating conditions. The end-tidal concentration (SD) of sevoflurane for successful tracheal intubation in 50% of children (ED(50)) were 5.16 (0.22)% in control, 3.27 (0.18)%, 1.81 (0.20)% and 1.01 (0.11)%, in remi(0.1), remi(0.2), and remi(0.3) groups, respectively. Using probit analysis, the 95% effective dose (ED(95)) of sevoflurane were 5.60% (95% CI 5.35-7.66), 3.77% (95% CI 3.45-7.74), 2.18% (95% CI 1.96-3.86), 1.19% (95% CI 1.06-1.82) in control, remi(0.1), remi(0.2), and remi(0.3) groups, respectively.
Medical subject headings
- Anesthetics, Inhalation
- Anesthetics, Intravenous
- Methyl Ethers
- Piperidines